Neonatal monosodium glutamate increases ethanol susceptibility effects in adult mice

Proceedings of the Western Pharmacology Society

Volumn 45, Issue , 2002, Pages 44-46

  Campos Sepulveda, Alfonso Efrain ^a   Ayala Guerrero, Fructuoso ^a   Rubio Poo, Consuelo ^a   Roman Ramos, Ruben ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; GLUTAMATE SODIUM; CENTRAL DEPRESSANT AGENT;

ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ARCUATE NUCLEUS; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GABAERGIC SYSTEM; HYPOTHALAMUS; HYPOTHERMIA; LD 50; MEDIAN EMINENCE; MOUSE; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; OBESITY; WEIGHT REDUCTION; ANIMAL; ANIMAL BEHAVIOR; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; DOSE RESPONSE; DRUG EFFECT; NEWBORN; PATHOPHYSIOLOGY; TOXICITY AND INTOXICATION;

ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BODY TEMPERATURE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; FEMALE; LETHAL DOSE 50; MICE; NEUROTOXICITY SYNDROMES; SODIUM GLUTAMATE;

EID: 0036034527     PISSN: 00838969     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Curtis DR & Watkins JC: J Neurochem 6: 117 (1960).
2. Collingridge GL & Lester RAJ: Pharmacol Rev 41: 143 (1989).
3. Nicoletti F, Bruno V, Copani A, Casabona G & Knopfel T: TINS 19: 267 (1996).
4. Bliss TVP & Collingridge GL: Nature 361: 31 (1993).
5. Staubli U, Rogers G & Lynch G: Proc Natl Acad Sci 91: 777 (1994).
6. McGaugh JL & Izquierdo I: TIPS 21: 208 (2000).
7. Collingridge GL & Singer W: TIPS II: 290 (1990).
8. Bortolotto ZA & Collingridge GL: Neuropharmacol 32: 1 (1993).
9. Arai A & Lynch G: Brain Res 598: 173 (1992).
10. Bashir ZI, Bortolotto ZA, Davies CH, Berreta N, Irving AJ, Seal AJ, Henley JM, Jane DE, Watkins JC & Collingridge GL: Nature 363: 347 (1993).
11. Lucas DR & Newhouse JP: AMA Arch Ophthalmol 58: 193 (1957).
12. Olney JW: Science 164: 717 (1969).
13. Kizer JS, Nemeroff CHB & Youngblood WW: Pharmacol Rev 29: 301 (1978).
14. Meister B, Ceccatelli S, Hokfelt T, Anden NE, Andén M & Theodorsson E: Exp Brain Res 76: 343 (1989).
15. Meister B: Methods in Neurosciences USA, Acad Press, vol 7 (1991).
16. Chambille I & Serviere J: J Comp Neurol 338: 67 (1993).
17. Olney JW: Biol Psychiatry 26: 505 (1989).
18. Mody I & McDonald JF: TIPS 16: 356 (1995).
19. Danysz W, Parsons CG, Bresink I & Quack G: Drug News Perspect 8: 261 (1995).
20. Schoepp DD & Conn PJ: TIPS 14:13 (1993).
21. Wisden W & Seeburg PH: Curr Opin Neurobiol 3: 291 (1993).
22. Dingledine R, Borges K, Bowie D & Traynelis S: Pharmacol Rev 51: 8 (1999).
23. Alexander SPH, Mathie A & Peters JA: TIPS Twelfth Ed. 1 (2001).
24. Litchfield JT & Wilcoxon F: J Pharmacol Exp Ther 96: 99 (1949).
25. Glowinsky J & Iversen LL: J Neurochem 13: 655 (1966).
26. Suzdak PD, Schwartz RD, Skolnick P & Paul SM: Proc Natl Acad Sci USA 83: 4071 (1986).
27. Beas ZC, Sanchez RMY, Urefia GME & Feria VA: Neurochem Intemac 33: 217 (1998).
28. Jennes L, Stump WE, Bissette G & Nemeroff CB: Brain Res 308: 245 (1984).
29. Di Giorgio RM, De Luca GC, Garofalo MP, Conti C & Lentile R: Italian J Biochem 34: 19 (1985).